Recovery of PEX1-gly843Asp peroxisome dysfunction by small-molecule compounds

Rui Zhang, Li Chen, Sarn Jiralerspong, Ann Snowden, Steven Steinberg, Nancy Braverman

Research output: Contribution to journalArticle

Abstract

Zellweger spectrum disorder (ZSD) is a heterogeneous group of diseases with high morbidity and mortality caused by failure to assemble normal peroxisomes. There is no therapy for ZSD, but management is supportive. Nevertheless, one-half of the patients have a phenotype milder than classic Zellweger syndrome and exhibit a progressive disease course. Thus, patients would benefit if therapies became available and were instituted early. Recent reports indicate several interventions that result in partial peroxisome recovery in ZSD fibroblasts. To identify drugs that recover peroxisome functions, we expressed a GFP-peroxisome targeting signal 1 reporter in fibroblasts containing the common disease allele, PEX1-p.Gly843Asp. The GFP reporter remained cytosolic at baseline, and improvement in peroxisome functions was detected by the redistribution of the GFP reporter from the cytosol to the peroxisome. We established a high-content screening assay based on this phenotype assay and evaluated 2,080 small molecules. The cells were cultured in chemical for 2 days and then, were fixed and imaged by epifluorescent microscopy on a high-content imaging platform. We identified four compounds that partially recover matrix protein import, and we confirmed three using independent assays. Our results suggest that PEX1-p.G843D is a misfolded protein amenable to chaperone therapy.

Original languageEnglish (US)
Pages (from-to)5569-5574
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume107
Issue number12
DOIs
StatePublished - Mar 23 2010
Externally publishedYes

Fingerprint

Peroxisomes
Zellweger Syndrome
Fibroblasts
Phenotype
Cytosol
Microscopy
Cultured Cells
Proteins
Therapeutics
Alleles
Morbidity
Mortality
Pharmaceutical Preparations

Keywords

  • AAA ATPase
  • Chemical screening
  • Misfolded protein
  • Pharmacologic chaperone
  • Zellweger spectrum

ASJC Scopus subject areas

  • General

Cite this

Recovery of PEX1-gly843Asp peroxisome dysfunction by small-molecule compounds. / Zhang, Rui; Chen, Li; Jiralerspong, Sarn; Snowden, Ann; Steinberg, Steven; Braverman, Nancy.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, No. 12, 23.03.2010, p. 5569-5574.

Research output: Contribution to journalArticle

Zhang, Rui ; Chen, Li ; Jiralerspong, Sarn ; Snowden, Ann ; Steinberg, Steven ; Braverman, Nancy. / Recovery of PEX1-gly843Asp peroxisome dysfunction by small-molecule compounds. In: Proceedings of the National Academy of Sciences of the United States of America. 2010 ; Vol. 107, No. 12. pp. 5569-5574.
@article{27f08a3736c743d0bebbabb5c96de1b2,
title = "Recovery of PEX1-gly843Asp peroxisome dysfunction by small-molecule compounds",
abstract = "Zellweger spectrum disorder (ZSD) is a heterogeneous group of diseases with high morbidity and mortality caused by failure to assemble normal peroxisomes. There is no therapy for ZSD, but management is supportive. Nevertheless, one-half of the patients have a phenotype milder than classic Zellweger syndrome and exhibit a progressive disease course. Thus, patients would benefit if therapies became available and were instituted early. Recent reports indicate several interventions that result in partial peroxisome recovery in ZSD fibroblasts. To identify drugs that recover peroxisome functions, we expressed a GFP-peroxisome targeting signal 1 reporter in fibroblasts containing the common disease allele, PEX1-p.Gly843Asp. The GFP reporter remained cytosolic at baseline, and improvement in peroxisome functions was detected by the redistribution of the GFP reporter from the cytosol to the peroxisome. We established a high-content screening assay based on this phenotype assay and evaluated 2,080 small molecules. The cells were cultured in chemical for 2 days and then, were fixed and imaged by epifluorescent microscopy on a high-content imaging platform. We identified four compounds that partially recover matrix protein import, and we confirmed three using independent assays. Our results suggest that PEX1-p.G843D is a misfolded protein amenable to chaperone therapy.",
keywords = "AAA ATPase, Chemical screening, Misfolded protein, Pharmacologic chaperone, Zellweger spectrum",
author = "Rui Zhang and Li Chen and Sarn Jiralerspong and Ann Snowden and Steven Steinberg and Nancy Braverman",
year = "2010",
month = "3",
day = "23",
doi = "10.1073/pnas.0914960107",
language = "English (US)",
volume = "107",
pages = "5569--5574",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "12",

}

TY - JOUR

T1 - Recovery of PEX1-gly843Asp peroxisome dysfunction by small-molecule compounds

AU - Zhang, Rui

AU - Chen, Li

AU - Jiralerspong, Sarn

AU - Snowden, Ann

AU - Steinberg, Steven

AU - Braverman, Nancy

PY - 2010/3/23

Y1 - 2010/3/23

N2 - Zellweger spectrum disorder (ZSD) is a heterogeneous group of diseases with high morbidity and mortality caused by failure to assemble normal peroxisomes. There is no therapy for ZSD, but management is supportive. Nevertheless, one-half of the patients have a phenotype milder than classic Zellweger syndrome and exhibit a progressive disease course. Thus, patients would benefit if therapies became available and were instituted early. Recent reports indicate several interventions that result in partial peroxisome recovery in ZSD fibroblasts. To identify drugs that recover peroxisome functions, we expressed a GFP-peroxisome targeting signal 1 reporter in fibroblasts containing the common disease allele, PEX1-p.Gly843Asp. The GFP reporter remained cytosolic at baseline, and improvement in peroxisome functions was detected by the redistribution of the GFP reporter from the cytosol to the peroxisome. We established a high-content screening assay based on this phenotype assay and evaluated 2,080 small molecules. The cells were cultured in chemical for 2 days and then, were fixed and imaged by epifluorescent microscopy on a high-content imaging platform. We identified four compounds that partially recover matrix protein import, and we confirmed three using independent assays. Our results suggest that PEX1-p.G843D is a misfolded protein amenable to chaperone therapy.

AB - Zellweger spectrum disorder (ZSD) is a heterogeneous group of diseases with high morbidity and mortality caused by failure to assemble normal peroxisomes. There is no therapy for ZSD, but management is supportive. Nevertheless, one-half of the patients have a phenotype milder than classic Zellweger syndrome and exhibit a progressive disease course. Thus, patients would benefit if therapies became available and were instituted early. Recent reports indicate several interventions that result in partial peroxisome recovery in ZSD fibroblasts. To identify drugs that recover peroxisome functions, we expressed a GFP-peroxisome targeting signal 1 reporter in fibroblasts containing the common disease allele, PEX1-p.Gly843Asp. The GFP reporter remained cytosolic at baseline, and improvement in peroxisome functions was detected by the redistribution of the GFP reporter from the cytosol to the peroxisome. We established a high-content screening assay based on this phenotype assay and evaluated 2,080 small molecules. The cells were cultured in chemical for 2 days and then, were fixed and imaged by epifluorescent microscopy on a high-content imaging platform. We identified four compounds that partially recover matrix protein import, and we confirmed three using independent assays. Our results suggest that PEX1-p.G843D is a misfolded protein amenable to chaperone therapy.

KW - AAA ATPase

KW - Chemical screening

KW - Misfolded protein

KW - Pharmacologic chaperone

KW - Zellweger spectrum

UR - http://www.scopus.com/inward/record.url?scp=77950409779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950409779&partnerID=8YFLogxK

U2 - 10.1073/pnas.0914960107

DO - 10.1073/pnas.0914960107

M3 - Article

C2 - 20212125

AN - SCOPUS:77950409779

VL - 107

SP - 5569

EP - 5574

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 12

ER -